BBI Solutions has announced the launch of ten infectious disease markers, three inflammatory markers, two fertility markers and an additional cardiac marker. All the antibodies have been tested in either lateral flow or ELISA and are available for sampling. BBI Solutions is in a rapid period of expansion and growth with recent announcements of a … Continue reading More antibodies added to BBI Solutions’ portfolio

BBI Solutions has invested in its facilities and resources to increase the capacity of cell culture transferrin production by up to 40% (Pharma Integrates, 2017). Stephane Argivier, BBI’s Director of Product Management, said “Demand for our cell culture grade transferrin was growing at such a rate that we had reached our full capacity. In response … Continue reading BBI Solutions increases capacity for cell culture native human transferrin production

BBI Solutions have launched over twenty new antibodies, extending their portfolio to include new cardiac, cancer, inflammation and fertility markers after reacting to demands in the marketplace (BBI Solutions, 2017). The antibodies come in a range of monoclonal and polyclonal varieties and are available for sampling. BBI have noticed that interest in fertility markers has … Continue reading BBI Solutions expand their antibodies product portfolio

BBI Group has today announced the completion of its acquisition by Exponent Private Equity (MediWales, 2017). Commenting on the deal, BBI Group CEO Lyn Rees said “This acquisition represents a firm commitment to the future growth plan of BBI, with the new ownership backed by a proven track record in the investment of resources for … Continue reading BBI Group acquired by Exponent Private Equity

BBI Group is consolidating and expanding its UK manufacturing operations onto a single site in Caerphilly in an £8.5m investment, supported by the Welsh Government, that will create and safeguard more than three hundred and sixty jobs in Wales (Welsh Government, 2017). BBI Group, which is currently headquartered in Cardiff, has a number of manufacturing … Continue reading BBI Group and the Welsh Government announce multi-million pound investment

Cardiff-based BBI Solutions, a leading developer and manufacturer of raw materials and finished test platforms for the in-vitro diagnostics market, has announced the launch of Porcine Liver Esterase (PLE), a new enzyme for urinalysis (BBI Solutions, 2016). PLE is used in urinalysis controls as a partial substitute and potentially cost effective alternative for human leukocyte … Continue reading BBI Solutions launches its first urinalysis enzyme